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Conclusion: Postoperative ALC is a significant prognostic 
factor for resected pancreatic cancer patients. Postoperative 
immune status might help to predict survival outcome and to 
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Purpose or Objective: To investigate prognostic factors for 
overall survival (OS) in hepatocellular carcinoma (HCC) 
patients treated with external beam radiotherapy (RT) for 
lymph node (LN) metastasis. 
 
Material and Methods: Between 2004 and 2015, 105 HCC 
patients underwent palliative RT for LN metastasis. The 
median age was 60 years (range, 30–82). Biologically 
effective radiation doses of 39–75 Gy10 (median, 59.0 Gy10) 
were delivered. The median follow-up period was 5.7 
months. 
 
Results: The median OS was 5.8 months. On univariate 
analysis, young age, symptoms related to LN metastasis, poor 
performance status, Child-Pugh class B–C, uncontrolled 
intrahepatic disease, non-nodal distant metastasis (DM), 
multi-station LN metastasis, biologically effective dose <60 
Gy10, lack of local response to RT, and stable or increased 
post-RT alpha-fetoprotein levels compared to pre-RT levels 
were significant prognostic factors predicting poor OS (all 
p<0.05). On multivariate analysis among pre-RT factors, 
symptoms related to metastatic LNs (HR, 2.93), Child-Pugh 
class B–C (HR, 2.77), uncontrolled intrahepatic disease (HR, 
2.74), and non-nodal DM (HR, 1.62) were significant 
prognostic factors for poor OS (all p<0.05). Risk stratification 
in 4 groups by the number of risk factors had a significant 
predictive value for OS, with patients having 0, 1, 2, and 3–4 
risk factors demonstrating median OS intervals of 18.0, 11.7, 
5.7, and 3.0 months, respectively (p<0.001). 
 
Conclusion: Our risk stratification model can be used 
effectively in assessing the life expectancy of the HCC 
patient before initiating palliative RT for LN metastasis. 
Moreover, the presence of symptoms related to LN metastasis 
was shown to be the most powerful indicator of poor OS. 
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Purpose or Objective: Sarcopenia is a major hallmark of 
cancer cachexia and associated with increased treatment 
toxicity and worse overall survival in cancer patients. The 
aim of the study is to investigate the incidence and course of 
sarcopenia in patients undergoing curative trimodality 
therapy for locally advanced esophageal cancer and to 
correlate skeletal muscle mass with treatment complications 
during neoadjuvant treatment and surgery. 
 
Material and Methods: A subset of 31 patients treated in a 
prospective trial for locally advanced esophageal cancer with 
induction chemotherapy, neoadjuvant chemoradiation and 
surgical resection were identified at two institutions and 
clinical data was analyzed for treatment-related adverse 
events and consequent additional hospitalizations. Skeletal 
muscle mass was obtained by a second analysis of staging CTs 
before, during and after curative trimodality therapy and 
analyzed based on previously established threshold values for 
sarcopenia. 
 
Results: Fourteen patients (45%) were characterized as 
sarcopenic at the initial staging. Unplanned hospitalizations 
occurred significantly more frequently in sarcopenic patients 
(71% vs. 29%, p = 0.03) with a significantly longer total 
duration of hospital stay including postoperative stay (median 
33.5 vs. 21.3 days, p < 0.05). During neoadjuvant therapy 
with a median duration of 3.5 months, patients showed a 
statistically significant reduction of of skeletal muscle mass 
of 10.1% (p < 0.01) resulting in an increase in the prevalence 
of sarcopenia from 45% to 74%. 
 
Conclusion: CT-based assessment of sarcopenia demonstrates 
a significant decline of muscle mass during curative 
trimodality therapy for locally advanced esophageal cancer 
and can predict toxicity-related unplanned hospitalization. 
Based on these findings, CT-based measurement of muscle 
mass may serve as objective parameter to identify frail 
patients in need of intensified supportive therapy. 
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Purpose or Objective: Loco-regional recurrence of 
esophageal cancer (REC) after initial treatment remains a 
dominant cause of death. Treatment options for REC are 
limited. This study was realized to assess the survival and 
symptom relief after salvage radio(chemo)therapy for 
recurrent esophageal cancer. 
 
Material and Methods: Data from 259 patients from 3 centers 
were retrospectively reviewed to screen for eligible patients. 
194 patients were excluded because of following criteria: 1) 
no pathologically confirmed squamous cell carcinoma or 
adenocarcinoma; 2) distant metastasis; 3) no dose-volume 
histogram (DVH) data available; 4) salvage resection after 
REC; 5) Brachytherapy in the initial or current treatment. 
Between January 1998 to December 2014 sixty-five patients 
with REC after curative intended treatment (primary RCT or 
surgical resection with or without neoadjuvant 
radiochemotherapy) met our inclusion criteria 
retrospectively. The recurrence was diagnosed by computed 
tomography (CT) and/or upper gastrointestinal endoscopy. 
The initial treatment was as follows: surgical resection in 47 
patients (72%), neoadjuvant RCT (median 50,4Gy, range 45-
50,4Gy) plus surgery in 12 (19%) patients or definitive RCT 
(median 60Gy, range 50,4-64 Gy) in 6 patients (9%). The 
median time to recurrence from initial treatment was 16 
months (range 3-101 months). 
 
Results: Median follow-up time for surviving patients was 27 
months (5-150 months). The 1-year and 2-year survival rates 
were 58 ± 6% and 27 ± 6%, respectively. Subjective symptom 
relief was achieved in 25 of 34 symptomatic patients (74%). 
The most common toxicities were leukopenia, nausea, 
vomiting and gastritis. RT Doses ³ 50Gy and ECOG-PS (1-2 vs. 
3) associated with better median survival time (MST) and 
prognosis, respectively (p=0.003;p=0.001).  
 
Conclusion: Salvage radio(chemo)therapy for recurrent 
esophageal cancer is a reliable option in patients suffering 
from REC. In particular therapy of symptoms caused by the 
tumor can be managed by salvage-RCT. The toxicity is in an 
acceptable range. Long-term survival is possible in some 
patients. 
 
